The Role of Salt Reduction in Hypertension Management: New Evidence and Global Initiatives
Last Updated:
Recent epidemiological data reaffirms that excessive sodium intake is inextricably linked to dysfunction of the vascular system, which in turn leads to cardiac issues, hypertension
Salt—an ubiquitous ornament that graces tables across continents—has in recent times emerged as a central villain in the narrative of hypertension. In human physiology, salt plays a crucial role in maintaining the body's mineral content; however, the perils of excess have recently come to light.
There is enough data—a burgeoning body of evidence—that addresses the benefits of curbing salt intake in hypertensive individuals. It is termed a silent predator that transforms healthy individuals into hypertensive patients. Even the young are not excluded from its effects. In fact, processed and stored foods, which are notorious for their high sodium chloride content, are largely consumed by the younger population.
Dr. Kayan Siodia, Consultant Cardiologist, P. D. Hinduja Hospital & Medical Research Centre, Khar, Mumbai, shares evidence about the role of salt reduction in hypertension management.
Recent epidemiological data reaffirms what many experts have long postulated: excessive sodium intake is inextricably linked to dysfunction of the vascular system, which in turn leads to cardiac issues and hypertension. Diets that have been widely studied and accepted—particularly the DASH (Dietary Approaches to Stop Hypertension) diet—demonstrate that even modest reductions in daily salt consumption can significantly lower both systolic and diastolic blood pressure. These findings offer true relief for the hypertensive population, grounded in data and time-tested results.
Multifaceted campaigns have been launched in response to the growing hypertension crisis. Ambitious—yet achievable—targets have been set by the World Health Organization (WHO) to reduce global salt intake by 30% by 2027. Many countries, including India, have risen to the challenge with renewed fervour and enthusiasm. Clear salt labelling and mandatory nutritional disclosures on packaged foods are now enforced in India, empowering consumers to make informed choices. A wave of culinary reimagining is steering us toward a salt-conscious era.
The omnipresence of salt in food remains a formidable hurdle. This journey is not without its impediments. However, the path forward is clear. Reducing even a small quantity of salt is a meaningful starting point for individuals with hypertension. It should be noted that salt reduction is not a substitute for prescribed medications, but rather a valuable adjunct in achieving better blood pressure control.
First Published:
May 04, 2025, 11:03 IST
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
17 minutes ago
- Business Standard
NB.1.8.1 Covid-19 variant makes up 10% cases globally: Should you worry?
Just when many believed Covid-19 was in the rear-view mirror, a new variant has quietly gained ground. NB.1.8.1, first detected in China in January 2025, now accounts for one in ten Covid-19 cases globally—up from just one in forty a month ago. It has spread across twenty-two countries so far. What is NB.1.8.1 variant? According to the World Health Organization, NB.1.8.1 is among several fast-evolving Omicron-lineage variants. From January to May 2025, global dominance shifted from XEC to LP.8.1, with NB.1.8.1 now surging rapidly. The WHO has classified NB.1.8.1 as a Variant Under Monitoring due to its rise in prevalence and potential public health implications. Officials stress that while vigilance is crucial, there is no cause for alarm. Vaccination remains the best protection against severe illness and death. How NB.1.8.1 behaves and how severe it really is NB.1.8.1 is a sublineage of the Omicron JN.1 family. It carries similar characteristics—high transmissibility, but mostly mild to moderate illness. It also includes new mutations on the spike protein, which may enhance its ability to spread and evade immunity. So far, there is no evidence to suggest NB.1.8.1 causes more severe disease, hospitalisations or death compared to previous variants. NB.1.8.1 symptoms: What to watch for Common symptoms include: Dry, persistent cough Runny or blocked nose Fatigue and general body aches Sore throat Fever or chills Headache or hoarseness in some cases Many report being able to go about daily activities but feel unusually tired and sluggish. Are vaccines still effective against NB.1.8.1? Updated vaccines, including the latest Omicron-targeted boosters, are designed to protect against the JN.1 family. While they may not prevent all infections, they continue to reduce the risk of hospitalisation and severe outcomes. Expert guidance includes: If you are over sixty, have chronic health conditions or are immunocompromised, get a booster if it has been more than six months since your last dose If you are healthy and under sixty, no new dose is required at present Use masks in public transport and crowded indoor spaces How to manage NB.1.8.1 symptoms at home In most cases, NB.1.8.1 does not require hospitalisation. Here is what helps: Rest and stay well hydrated Use paracetamol or other over-the-counter medications for fever or aches Recovery generally takes five to seven days If you are elderly or immunocompromised, speak to your doctor early. Antiviral medication is most effective within five days of the onset of symptoms. Warning signs: When to seek emergency help Seek urgent medical care if you experience any of the following: Difficulty breathing Chest pain or tightness Confusion or trouble staying awake Severe dizziness or fainting Do not panic, but stay informed Experts believe NB.1.8.1 will follow a familiar seasonal pattern seen with earlier variants—periodic surges during winter and summer months. Most infections remain mild. Vaccines continue to work. Keep an eye on symptoms, isolate if unwell, and consult your doctor when in doubt.
Hans India
an hour ago
- Hans India
Consumer Choice Center Advocates for Significant Revisions to WHO Governance and Operations Amidst Approval of Increased Mandatory Membership
India: The World Health Organization (WHO) is facing intense scrutiny following the approval of a 20% increase in mandatory membership dues, amounting to an additional $120 million per year extracted directly from taxpayers Consumer Choice Center joins critics in questioning whether the organization truly deserves this financial boost, citing significant issues with transparency, accountability, and the allocation of funds. In a country like India, where over 60% of health expenditure is out-of-pocket and public health systems remain severely underfunded, questions around the WHO's spending priorities resonate deeply. The World Health Organization (WHO) recently announced an increase in its mandatory membership dues-known as assessed contributions—by 20%. For 2026 and 2027, this will amount to an additional $120 million per year , drawn straight from taxpayers around the globe. The WHO allocates funding through both voluntary contributions, which are earmarked for specific health programs, and assessed contributions. Assessed contributions provide the WHO leadership, including Director-General Tedros Adhanom Ghebreyesus, with greater discretion in how the funds are utilized. These funds are directed into flexible funding streams. This occurs while global healthcare systems experience challenges related to underfunding, growing waitlists, and staff shortages. Funds are being allocated to various initiatives, including upgrades to the WHO's Geneva headquarters. Senior staff benefits include education allowances of $33,000 per child. The total annual cost for the WHO's 301 most senior staff is approximately $130 million, averaging $432,000 per person, inclusive of benefits and allowances. Sharing his thoughts on the potential utilisation of these additional funds, Fred Roeder, Managing Director, Consumer Choice Center said, 'The $120 million being extracted in new dues each year could directly fund healthcare for 15,000 Germans, 40,000 Poles, 82,000 Georgians, 100,000 South Africans and 500,000 Indians . In India, $120 million annually could fund cancer treatment for 40,000 patients under Ayushman Bharat or cover the full immunization of over 2 million children. That same amount could also strengthen tobacco cessation services across the country, which remain vastly under-resourced despite India having over 260 million tobacco users . Even more troubling, this shift toward 'core funding' is part of a deliberate WHO strategy: to move away from specific, donor-driven initiatives and toward general budget increases it can spend at will—on salaries, travel, and yes, real estate. These are not funds being poured into pandemic preparedness or child vaccination programs. They are being funnelled into a top-heavy administrative structure with minimal transparency and questionable accountability.' The WHO's defenders argue that the organization needs more freedom to respond to global health threats. But freedom without scrutiny leads to mission drift and misallocation. The organization already has a poor record of pandemic response and a reputation for political entanglements. Its handling of tobacco control in India reflects this too—offering ideological prescriptions rather than collaborative, evidence-based support that balances public health, trade, and economic development. The last thing it needs is a blank check. The world needs a lean, targeted health response team. Let's refocus the WHO on solving global health crises, prioritizing impact over institutional expansion. National governments should refuse further increases to assessed contributions until the WHO commits to radical transparency reforms, trims senior compensation packages, and rededicates itself to programmatic funding that puts patient care first. We owe that much to the people who are actually sick—and not just those with corner offices in Geneva. India, as a G20 leader and a major player in global health diplomacy, should demand accountability before committing more taxpayer funds. It must condition future WHO funding on results-driven support for local challenges—like modernizing tobacco regulation, enabling farmer transitions, and enforcing traceability to combat the illicit trade that harms both public health and revenue. Consumer Choice Center The Consumer Choice Center is an independent, non-partisan consumer advocacy group championing the benefits of freedom of choice, innovation, and abundance in everyday life. Through research and educational outreach, we advocate for smart policies that promote growth, lifestyle choice, and tech innovation. We empower consumers to raise their voice and fight for their right to choose—whether it's the products they buy, the technologies they use, or the lifestyle they live.
Time of India
an hour ago
- Time of India
We can forget COVID-19, it's not a cause for concern, say health experts, as they explain the reason behind the surge in India
COVID-19 is becoming milder, but occasional surges are expected. Experts say the virus is endemic and constantly evolving. Rising cases are due to waning immunity and seasonal factors. Vulnerable populations should take precautions. The WHO declared the end of COVID-19 as a public health emergency two years ago. Cases are rising in Southeast Asia, including India. Tired of too many ads? Remove Ads Covid Becoming Milder Every Passing Year: Expert Tired of too many ads? Remove Ads Surge in India part of broader trend Tired of too many ads? Remove Ads 'Ups and downs expected because the virus is endemic' COVID-19 is becoming less severe over time, but occasional increases in cases are expected as the virus becomes endemic and continues to change, scientists say. They reassure the public that there is no major cause for alarm. The experts addressed concerns about the rising number of cases in different parts of India . They believe it is due to weakening immunity combined with seasonal factors, such as extreme temperatures that cause people to stay indoors in air-conditioned environments. They emphasised the need for caution, especially for those who are more vulnerable."With every passing year, COVID-19 is causing milder infections. It is (now) just another respiratory illness and less dangerous than flu. We can forget COVID-19 as a special case. It is not a cause of concern," said Dr. Chandrakant Lahariya, a global health Agarwal from Ashoka University added, "All the subvariants are similar, having a lower virulence but high infectivity. While highly susceptible people can still get severe disease, the vast majority don't, especially those who have had prior infections or vaccines."The World Health Organization (WHO) declared the end of COVID-19 as a public health emergency in May 2023. Health experts now describe the disease as seasonal, endemic, or restricted to certain of June 6, there were over 5,300 active cases in India, with nearly 500 new cases reported in the last 24 hours. More than 4,700 people have recovered. Since January, 55 deaths have been reported, mainly among individuals with pre-existing conditions, according to the Union Health advised that "People with pre-existing illnesses and those older than 65 should follow standard precautions, as they would against any other respiratory infection -- not just for COVID-19."Kerala is the most affected state with over 1,600 cases, followed by Gujarat, West Bengal, Delhi, and Maharashtra, according to ministry increase in cases in India is part of a broader trend in Southeast Asia, including Singapore, Malaysia, Thailand, and Hong surveillance by the Council of Scientific and Industrial Research-National Chemical Laboratory (NCL) has detected the presence of the virus in samples from sewage treatment plants in Pune, according to the Times of sequencing of samples from western and southern India has shown links to Omicron subvariants LF.7, XFG, JN.1, and NB.1.8.1. Rajiv Behl, Director General of the Indian Council of Medical Research (ICMR), said earlier this week that the cases are not severe and there is no need to WHO has classified LF.7 and NB.1.8.1 as 'variants under monitoring' (VUM). JN.1 has been circulating in India since November Satyajit Rath explained that the subvariants are likely better at binding to human cells, despite existing antibodies."However, the important issue here is not their infectivity, but their tendency to cause severe disease, or 'virulence'," Rath experts said that ups and downs in infections are expected because the virus is now endemic and constantly stated, "People need not worry themselves until they are informed of a new 'variant of concern'. VUM is not relevant to the public, but only to public health authorities."Lahariya advised the public to get information from reliable sources and avoid sharing unverified messages. Rath suggested monitoring the virulence of new emphasised that "National and state governments in India should keep a watch on cases, monitor the trends in new cases and share data widely. The linkage between infections and clinical outcomes should be explored to understand the clinical features of the variants in circulation."Rath highlighted the need to address systemic issues in public health systems and healthcare questioned, "Are we making next-generation Covid vaccines at all? Are we making them available widely and affordably? Are we even carefully tracking evidence to see how well or poorly the current vaccine-induced immunity functions against emerging strains?"He added, "And if not, we are throwing poor communities onto their own resources even for taking such simple precautions, and that is a systemic problem."(Inputs from PTI)
